Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies
N A Wages1, C L Slingluff2, G R Petroni1
1Department of Public Health Sciences, Division of Translational Research & Applied Statistics, University of Virginia, Charlottesville, Virginia, USA.
Background:
In recent years, investigators have asserted that the 3 + 3 design lacks flexibility, making its use in modern early-phase trial settings, such as combinations and/or biological agents, inefficient. More innovative approaches are required to address contemporary research questions, such as those posed in trials involving immunotherapies.
Design:
We describe the implementation of an adaptive design for identifying an optimal treatment regimen, defined by low toxicity and high immune response, in an early-phase trial of a melanoma helper peptide vaccine plus novel adjuvant combinations.
Results:
Operating characteristics demonstrate the ability of the method to effectively recommend optimal regimens in a high percentage of trials with reasonable sample sizes.
Conclusions:
The proposed design is a practical, early-phase, adaptive method for use with combined immunotherapy regimens. This design can be applied more broadly to early-phase combination studies, as it was used in an ongoing study of two small molecule inhibitors in relapsed/refractory mantle cell lymphoma.
Insights
This study introduces a flexible adaptive design for early-phase immunotherapy trials. The method efficiently identifies optimal treatment combinations with high immune response and low toxicity.
Area of Science:
- Clinical Trials
- Immunotherapy
- Oncology
Background:
- Traditional 3+3 trial designs are inflexible for modern early-phase studies, particularly those involving combination therapies and biological agents.
- Innovative approaches are needed to address complex research questions in contemporary clinical trials, including those with immunotherapies.
Purpose of the Study:
- To describe an adaptive design for identifying optimal treatment regimens in early-phase trials.
- To define optimal regimens by low toxicity and high immune response.
- To evaluate the design's application in a trial of melanoma vaccine plus adjuvant combinations.
Main Methods:
- Implementation of a novel adaptive design for early-phase clinical trials.
- Focus on identifying optimal treatment combinations for immunotherapy regimens.
- Evaluation of operating characteristics to assess design efficiency.
Main Results:
- The adaptive design effectively recommends optimal regimens in a high percentage of simulated trials.
- The method operates with reasonable sample sizes.
- Demonstrated ability to balance toxicity and efficacy endpoints.
Conclusions:
- The proposed adaptive design is a practical and effective method for early-phase combination immunotherapy studies.
- The design offers flexibility beyond traditional methods.
- Applicable to broader early-phase combination studies, including small molecule inhibitors for mantle cell lymphoma.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:20Comparing the Survival Analysis of Two or More Groups
01:20Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
01:16Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.